By Sandi Wong, Assistant Editor
Biopharmaceutical Report II
"THERE IS A HUGH DIFFERENCE BETWEEN THE POSSIBILITY THAT A VACCINE WILL SENSITIZE A SUSCEPTIBLE, SERONEGATIVE RECIPIENT TO AN ANTIBODY-ENHANCED DISEASE AND THE REALITY THAT IT ACTUALLY DOES."
SCOTT HALSTEAD, USUHS
The rush to make a vaccine for COVID-19 has raised concern that some candidate treatments could make infections worse. The main risk is the chance of inducing antibody-dependent enhancement, a process known to complicate vaccine development in Dengue and several other diseases.
The topic drew attention at a global online forum sponsored last month by WuXi Apptec Co. Ltd. (Shanghai:603259; HKEX:2359) (see “Plotting a Scientific Path to Counter COVID-19”). ADE is usually triggered by non-neutralizing antibodies or sub-neutralizing levels of antibodies. Two papers published in Cell and the Journal of Virology in February showed it can happen with neutralizing antibodies as well.
While it’s too early to know if COVID-19 carries a risk of ADE, other coronaviruses, including SARS-CoV and MERS-CoV, have been associated with the phenomenon, Scott Halstead, who introduced the ADE concept 40 years ago, told BioCentury.
This does not make ADE a foregone conclusion with COVID-19, Halstead noted. “There is a huge difference between the possibility that a vaccine will sensitize a susceptible (seronegative) recipient to an antibody-enhanced disease and the reality that it actually does.” Halstead is an adjunct professor at the Uniformed Services University of the Health Sciences.
For SARS and MERS, antibodies against the viruses -- elicited either by infection or vaccination -- have been shown to cause ADE in animal models, including non-human primates. In cell cultures, they have been shown to potentiate infection of primary human macrophages.
There’s also evidence that feline infectious peritonitis virus, a coronavirus that infects domestic cats, is enhanced both by maternal antibodies transferred to kittens and by vaccination, resulting in severe and fatal feline disease.
Halstead is unaware of any “evidence that severe or fatal SARS or MERS result from antibody-mediated infections.”
Vaccine developers “must be aware of and look for” the possibility of ADE caused by COVID-19 vaccines, he cautioned.
In Dengue, the phenomenon has held up vaccine development for several drug developers (see “Dengvaxia’s Warning”).
Johan Van Hoof, global therapeutic area head for infectious diseases and vaccines at Janssen unit of Johnson & Johnson (NYSE:JNJ), told BioCentury that ADE is linked to an imbalance of responses of two types of T cell, Th2 vs Th1, favoring the former.
Van Hoof thinks companies could use this fact during Phase I testing to demonstrate a low risk of ADE by showing their candidate induces a Th1-driven immune profile. Showing a vaccine candidate elicits neutralizing antibodies will also be important, he said.
Designing out ADE
A variety of vaccine design approaches have been proposed to help lower risk for ADE.
Most companies developing COVID-19 vaccines have not said whether they are using these or other approaches.
Kizzmekia Corbett, scientific lead of the coronavirus team at NIH’s vaccine research center, previously told BioCentury that the candidate from Moderna Inc. (NASDAQ:MRNA), mRNA-1273, which encodes the virus’ spike protein, incorporates mutations that stabilize the spike in a prefusion conformation to ensure it induces the right kind of antibodies to confer protection.
Peter Hotez, co-director of Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, told BioCentury his team’s strategy involves “reducing the size of the subunit vaccine” to focus the immune response on the receptor-binding domain of the spike protein.
CureVac AG spokesperson Thorsten Schüller told BioCentury the company took into account preclinical and animal data regarding coronavirus-associated ADE “for the design of our vaccine candidates for SARS-CoV-2 by carefully selecting the target protein.” He declined to disclose the details.
Janssen spokesperson Paul Graves told BioCentury the company is exploring approaches that “target all or some parts of the protein” for its vaccine and “will select which targets to pursue based on the results of our early research.”
Moderna’s mRNA-1273, partnered with NIH, will be among the first preventative vaccines to enter the clinic; it is scheduled to start Phase I testing Friday. The first clinical batch of mRNA-1273 was delivered 42 days after the genome of the virus that causes COVID-19 was released; design and manufacturing took 25 days.
CureVac hopes to have an mRNA vaccine in the clinic by June or July, and Janssen plans to take a candidate from its recombinant adenovirus (rAdV) vector platform into the clinic within a year.
More than three dozen companies and academic groups have announced COVID-19 vaccine programs (see “A Growing List of Vaccines” and “U.S. Testing of Coronavirus Vaccine, Therapeutic Begin”).
EDITORIAL & RESEARCH
NEWSROOM: firstname.lastname@example.org SAN CARLOS, CA: +1 650-595-5333 CHICAGO: +1 312-755-0798 WASHINGTON, DC: +1 202-462-9582 UNITED KINGDOM: +44 (0)1865-512184
BioCentury Innovations: Idea to IND BioCentury: Phase I to the Patient BioCentury Extra: Essential News for Biotech and Pharma
C. Simone Fishburn, Ph.D., Editor in Chief Editors Emeritus: Susan Schaeffer (2012-2018); Karen Bernstein, Ph.D. (1992-2012)
Jeff Cranmer, Selina Koch, Ph.D., Executive Editors
Steve Usdin, Senior Editor/Washington & Head: Policy & Regulation
Lauren Martz, Senior Editor, Head of Translation & Clinical Development
Karen Tkach Tuzman, Ph.D., Associate Editor & Head: Discovery and Preclinical Development
Paul Bonanos, Stephen Hansen, Virginia Li, Inhua Muijrers-Chen, Ph.D., Karen Tkach Tuzman, Ph.D., Associate Editors Meredith Durkin Wolfe, Winnie Pong, Ph.D., Associate Editors, Data & Analytics Sandi Wong, Ph.D., Assistant Editor Allison Johnson, Ph.D., Senior Writer Elizabeth S. Eaton, Hongjiang Li, Ph.D., Claire Quang, Staff Writers
CORPORATE, SUBSCRIPTIONS & PRIVACY
BioCentury’s mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury Inc. BioCentury International Inc.
MAIN OFFICES 1235 Radio Road, Ste. 100 Redwood City, CA 94065-1217 +1 650-595-5333; Fax: +1 650-595-5589
CORPORATE Karen Bernstein, Ph.D., Co-Founder & Chairman David Flores, Co-Founder, President & CEO C. Simone Fishburn, Ph.D., Vice President/Editor in Chief Adam Gordon: Vice President/ Product Management & Marketing David Smiling: Chief Technology Officer Bennet Weintraub: Vice President/ Administration & CFO Eric Pierce: Publisher Susan Morgan: Senior Director/Administration & Human Resources
BUSINESS DEVELOPMENT Joshua Berlin, Executive Director Juli Balestrieri, Kevin Lehnbeuter, Business Development Managers
PRODUCT MANAGEMENT & MARKETING Greg Monteforte, Director/Marketing & Promotional Services Josephine Asciutto-Bunn, Marketing Coordinator
SUBSCRIBER SERVICES Tim Tulloch, Senior Director Orlando Abello, Matt Krebs, Michelle Ortega, Ron Rabinowitz, Account Managers Hannibal Adofo, Marilyn Smith, Subscriber Services
TECHNOLOGY Jenny Nichols, Director/Publishing Lam Lu, Head/Business Intelligence Group
This edition and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.